Tweaking the Heart-Lung machine: a new strategy to prevent Post-Surgery strokes and clots?

NCT ID NCT07750548

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial tests a modified cardiopulmonary bypass (heart-lung machine) setup during emergency surgery for acute type A aortic dissection, a life-threatening condition. The new strategy aims to reduce the body's inflammatory response and lower the risk of new blood clots or embolisms in the brain, heart, and other organs. Adults aged 18-80 undergoing this surgery may participate. The study compares the modified setup to the standard one, tracking new ischemic or embolic lesions and complications over three years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A modified cardiopulmonary bypass (heart-lung machine) setup designed to reduce inflammation and blood clotting during surgery.
What this could lead to
If successful, this approach could lower the risk of serious complications like strokes and blood clots after emergency aortic surgery, improving recovery and survival.
What could go wrong
The trial is still in early stages, and the modified bypass may not reduce inflammation or complications as hoped. There are also standard risks of major heart surgery, including bleeding and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 270 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years old and under 80 years old, both male and female are eligible; 2. Patients planning to undergo open TAAAD surgery; 3. The patient voluntarily participates in this trial and signs an informed consent form. Exclusion Criteria: 1. History of tumors, mental illness, coagulation dysfunction, or hematological disorders; 2. Patients with preoperative thinking, language, or hearing communication disorders; 3. Severe preoperative liver and kidney dysfunction; 4. Critical preoperative states such as IABP, ECMO, and high-dose vasopressors; 5. Allergic to plastics, resins, or heparin; 6. Patients who refuse blood transfusions (Jehovah Witness); 7. Fever exceeding 38 ℃ or combined with systemic infection, sepsis; 8. Has participated in other blood related clinical studies. Eliminating criteria 1\) The patient requests revocation of informed consent and withdrawal from the study; 2) The included cases have had their surgeries cancelled due to various reasons, or the investigators believe that the intervention measures were not completed according to the plan; 3) The attending physician believes that continuing research is not beneficial for the patient.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dissection, aortic are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Aortic Dissection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.